Femasys Inc. shares fall 3.43% intraday despite UK regulatory approval for FemBloc.

Femasys Inc. declined 3.43% in intraday trading, despite the company announcing that it received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for its FemBloc permanent birth control, which signifies the product has met the required standards for safety, quality, and effectiveness in the United Kingdom (UK). This marks an important milestone in the Company’s efforts to expand availability of this revolutionary non-surgical permanent birth control option to women in Europe.